XML 54 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Benefits and Charges (Details)
$ in Millions
3 Months Ended 9 Months Ended
Oct. 02, 2016
USD ($)
Sep. 27, 2015
USD ($)
Oct. 02, 2016
USD ($)
site
Sep. 27, 2015
USD ($)
Dec. 31, 2015
USD ($)
Restructuring Cost and Reserve [Line Items]          
Number of International Sites Exited | site     1    
Provision     $ (17)    
Exit costs [1]     3    
Provision for losses on inventory     65 $ 59  
Accelerated depreciation     5    
Consulting fees $ 4 $ 8 11 28  
Gain (loss) recognized related to divestitures [2] 0 0 27 [3] 0  
Consulting fees     14    
Total costs associated with the operational efficiency initiative and supply network strategy 11 24 (23) 317  
Restructuring Reserve [Roll Forward]          
Beginning balance [4]     222    
Provision     (17)    
Utilization and other [5]     (101)    
Ending balance [4] 104   104    
Other current liabilities          
Restructuring Reserve [Roll Forward]          
Accrued expenses 70   70   $ 162
Other Noncurrent Liabilities          
Restructuring Reserve [Roll Forward]          
Other noncurrent liabilities 34   34   $ 60
Employee Termination Costs          
Restructuring Cost and Reserve [Line Items]          
Provision     (20)    
Restructuring Reserve [Roll Forward]          
Beginning balance [4]     221    
Provision     (20)    
Utilization and other [5]     (99)    
Ending balance [4] 102   102    
Exit Costs          
Restructuring Cost and Reserve [Line Items]          
Provision     3    
Restructuring Reserve [Roll Forward]          
Beginning balance [4]     1    
Provision     3    
Utilization and other [5]     (2)    
Ending balance [4] 2   2    
Operational Efficiency          
Restructuring Cost and Reserve [Line Items]          
Provision 4 8 (22) 261  
Asset impairment charges 0 8 0 33  
Exit costs 1 0 4 0  
Provision for losses on inventory 1 5 1 5  
Accelerated depreciation 0 0 1 0  
Gain (loss) recognized related to divestitures [1] 0 0 (27) 0  
Other cost reduction and cost productivity charges 5 13 (14) 33  
Restructuring Reserve [Roll Forward]          
Provision 4 8 (22) 261  
Operational Efficiency | Employee Termination Costs          
Restructuring Cost and Reserve [Line Items]          
Provision [6] 3 0 (26) 228  
Restructuring Reserve [Roll Forward]          
Provision [6] 3 0 (26) 228  
Supply Network Strategy          
Restructuring Cost and Reserve [Line Items]          
Provision 0 0 6 10  
Asset impairment charges 0 0 0 1  
Employee termination costs 0 0 6 9  
Accelerated depreciation 2 0 4 0  
Other cost reduction and cost productivity charges 2 3 7 13  
Consulting fees 0 3 3 13  
Restructuring Reserve [Roll Forward]          
Provision 0 0 6 10  
Zoetis Initiatives          
Restructuring Cost and Reserve [Line Items]          
Provision 4 8 (16) 271  
Exit costs 1        
Accelerated depreciation 2        
Consulting fees 4        
Restructuring Reserve [Roll Forward]          
Provision 4 8 (16) 271  
Zoetis Initiatives | Employee Termination Costs          
Restructuring Cost and Reserve [Line Items]          
Provision 3   (20)    
Restructuring Reserve [Roll Forward]          
Provision 3   (20)    
International [Member]          
Restructuring Cost and Reserve [Line Items]          
Provision (1) 2 (16) 117  
Restructuring Reserve [Roll Forward]          
Provision $ (1) $ 2 $ (16) $ 117  
[1] For the nine months ended October 2, 2016, represents the net gain on the sale of certain manufacturing sites and products, partially offset by the loss on the sale of our share of our Taiwan joint venture, as part of our operational efficiency initiative.
[2] For the nine months ended October 2, 2016, represents the net gain on the sale of certain manufacturing sites and products, partially offset by the loss on the sale of our share of a Taiwan joint venture, as part of our operational efficiency initiative.
[3] For the three and nine months ended October 2, 2016, represents an impairment of finite-lived trademarks related to a canine pain management product. For the nine months ended September 27, 2015, represents an impairment of IPR&D assets related to the termination of a canine oncology project.
[4] At October 2, 2016, and December 31, 2015, included in Accrued expenses ($70 million and $162 million, respectively) and Other noncurrent liabilities ($34 million and $60 million, respectively).
[5] Includes adjustments for foreign currency translation.
[6] For the nine months ended October 2, 2016, includes a reduction in employee termination accruals primarily as a result of higher than expected voluntary attrition rates experienced in the first half of 2016.